Showing 2331-2340 of 5065 results for "".
10 Tips for Managing Hidradenitis Suppurativa
https://practicaldermatology.com/issues/april-2025/10-tips-for-managing-hidradenitis-suppurativa/35602/In an effort to assist the working dermatologist, we have provided the following HS management guide, which supplies actionable insights into optimizing HS management, emphasizing the importance of individualized care, timely interventions, and collaboration with multidisciplinary teams.GLP-1RAs and the Dermatologist
https://practicaldermatology.com/issues/novemberdecember-2025/glp-1ras-and-the-dermatologist/48885/We are only beginning to understand the implications of GLP-1s for skin and systemic health. These medications are here to stay, and dermatology must be part of the conversation.Teledermatology Update: Restrictions Lifted Due to COVID-19
https://practicaldermatology.com/topics/practice-management/teledermatology-update-restrictions-lifted-due-to-covid-19/23256/Easing of guidelines may allow more practices to add teleconsults.Non-invasive “Mega” Laser Combinations: How to Achieve Maximal Results
https://practicaldermatology.com/topics/practice-management/non-invasive-mega-laser-combinations-how-to-achieve-maximal-results/21150/Improved outcomes and shortened downtime are just some of the advantages of multi-modality approaches to the evolving non-invasive aesthetic front.A Non-Invasive 2-Gene Molecular Assay Shows Promise in Assessment of Pigmented Lesions
https://practicaldermatology.com/topics/skin-cancer-photoprotection/a-non-invasive-2-gene-molecular-assay-shows-promise-in-assessment-of-pigmented-lesions/20705/More studies are needed, but a non-invasive assay that identified melanoma gene expression could support clinical decision making.DWTV Extra: New Tapinarof Data for AD
https://practicaldermatology.com/videos/dermwire-tv/dwtv-extra-new-tapinarof-data-for-ad/33940/Linda Stein Gold, MD, discusses the results from the Phase 3 ADORING 3 open-label, long-term extension study evaluating tapinarof cream, 1% once daily in children as young as 2 and adults with atopic dermatitis, presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in OrlandoA Closer Look at OX40 Pathway Modulation
https://practicaldermatology.com/programs/practical-dermatology-type-ii-inflammation-journal-club/a-closer-look-at-ox40-pathway-modulation/50890/Walter Liszewski, MD, talks with Matthew Zirwas, MD, about the potential therapeutic applications, based on the article “Targeting the OX40-OX40L pathway: A new era in atopic dermatitis management by T-cell rebalancing,”1 as well as the risks of therapies targeting the OX40 pathway.Sciton Resurfacing Laser Technologies - Patient Testimonials
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/sciton-resurfacing-laser-technologies-patient-testimonials--michisug/19484/Sciton Laser Technology treatments include Deep Resurfacing, MicroLaserPeel, ProFractional Therapy, and Combination Treatments to stimulate collagen, correct superficial imperfections almost immediately, and improve skin's texture & tone in just 1-4 treatment sessions.Dermwire TV: Topical Caffeine for Hair Growth, Tapinarof for Pediatric AD
https://practicaldermatology.com/videos/dermwire-tv/dermwire-tv-topical-caffeine-for-hair-growth-tapinarof-for-pediatric-ad/48734/This episode highlights studies showing potential for topical caffeine in hair growth in patients with alopecia areata, as well as recent positive results for tapinarof cream 1% for children with AD. Also, Cutera CEO Taylor Harris talks with Practical Dermatology about the evolving needs of today’sDermwireTV: Deucravacitinib Maintains Efficacy in PsO at 3 Years
https://practicaldermatology.com/programs/practical-dermatology/dermwiretv-deucravacitinib-maintains-efficacy-in-pso-at-3-years/37249/In this episode of DermwireTV, deucravacitinib maintains efficacy for plaque psoriasis through 3 years in a new analysis; GLP-1 medications may be fueling a rise in aesthetic procedures, according to new research; and Drs. Tina Bhutani and Lisa Swanson weigh in on transitioning from academia to priv